Patients with long standing type 1 diabetes were given 2 escalating doses of proinsulin peptide C19-A3 pulsed tolDCs intradermally or saline (the tolDC vehicle) for one patient in each cohort and monitored for 6 months (73). This evidence concerns the gene INS and type 1 diabetes mellitus.